The 2018 AHA/ACC/
Multi-society guideline recommends frequently testing your patients’ LDL-C1

Knowing your patients’ LDL-C helps you quickly identify their risk of having a CV event, adherence to lifestyle modifications, and effectiveness of treatment.

traetment

Frequent LDL-C testing is recommended by the 2018 AHA/ACC/Multi-society guideline1

* To assess adherence and response to change in lifestyle or LDL-C lowering therapy.

LDL-C is not being tested in most patients when their risk is highest1,2

Fewer than 1 in 4 patients with ASCVD who are at very high risk have their LDL-C tested after a recent myocardial infarction. Risk of another CV event is higher in patients with prior myocardial infarction than those without. LDL-C testing can reveal if there are issues with adherence to lifestyle recommendations or treatment.

Inadequate LDL-C testing rates following the most recent CV event3

Retrospective study using the IQVIA (Longitudinal Access and Adjudication data; LAAD) database of patients (N = 16,406,925) with ASCVD at very high risk who had a heart attack (January 2018 to December 2022).

VHR = very high risk.

testtube-one
testtube-mobile 1

Free LDL-C testing is available to your patients§

Terms and conditions apply. Programs subject to change; quantities may be limited. For details, visit: www.attackheartdisease.com/free-ldl-c-test.

icon-5

The 2022 ACC ECDP recommends lower LDL-C threshold for patients with ASCVD at very high risk2

AHA/ACC = American Heart Association/American College of Cardiology; ASCVD = atherosclerotic cardiovascular disease; ECDP = Expert Consensus Decision Pathway; LAAD = Longitudinal Access and Adjudication Data.

  • References

    1. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73:3168-3209.
    2. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80:1366-1418.
    3. Data on file, Amgen; 2023.